Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (9): 88-96.doi: 10.6040/j.issn.1671-7554.0.2019.790

Previous Articles     Next Articles

Analysis of risk factors and drug resistance of Acinetobacter baumannii in patients with chronic obstructive pulmonary disease

ZHANG Ning1, YANG Yan2, LI Rui2, YIN Yunhong2, LI Hao2, QU Yiqing2   

  1. 1. Department of Respiratory and Critical Care Medicine A Ward, Shandong Chest Hospital, Jinan 250013, Shandong, China;
    2. Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2022-09-27

Abstract: Objective To explore the risk factor of Acinetobacter baumannii(AB)infection and drug resistance in patients with chronic obstructive pulmonary disease(COPD)in order to provide a theoretical basis for treating AB infection in COPD patients. Methods The clinical data of inpatients treated during 2012 and 2015 were collected from departments of respiratory and respiratory intensive care unit, and 308 AB positive patients were selected according to the exclusion criteria. Drug-resistant bacteria and drug resistance were detected in 308 AB positive cases and 91 COPD cases with AB. A case control study was performed in 144 COPD patients, including 72 AB positive and 72 AB negative cases. 山 东 大 学 学 报 (医 学 版)57卷9期 -张宁,等.慢阻肺患者感染鲍曼不动杆菌危险因素及耐药性分析 \=- The risk factors associated with AB infection were determined with binary logistic regression analysis. Results (1) Single factor analysis showed that age, recent history of hospitalization, history of glucocorticoid and antibiotics use, invasive operations, chronic diseases, classification of lung function and frequency of exacerbations were statistically significant (P<0.05). Multivariate Logistic regression showed that invasive operation (OR=3.725, 95% CI=2.642-9.534), recent history of hospitalization (OR=3.417, 95%CI=1.412-8.515), classification of lung function (OR=2.835, 95%CI=1.012-9.853), history of glucocorticoid use (OR=2.815, 95%CI=1.328-9.045), chronic disease (OR=2.136, 95%CI=1.023-8.146), history of antibiotic use(OR=2.326, 95%CI=1.145-7.134), frequency of exacerbations (OR=2.823, 95%CI=1.012-9.853), age (OR=1.756, 95%CI=1.003-7.035) were independent risk factors of AB infection (P<0.05). (2) Drug resistance tests of AB positive patients showed that cefepime had the highest drug resistance rate(79.2%), while tegacycline had the lowest drug resistance rate(20.1%). (3) Compared to non-COPD patients, COPD patients with AB had higher resistance rates to imipenem(86.8% vs 59.4%), cefepime(93.4% vs 73.2%), levofloxacin(82.4% vs 57.6%), cefoperazone sulbactam(49.4% vs 29.0%)and tegacycline(27.5% vs 17.1%). The differences were statistically significant (P<0.05). Conclusion Chronic diseases, invasive operation, recent history of hospitalization, history of glucocorticoid and antibiotic use and classification of lung function are independent risk factors for COPD patients infected with AB. Compared with non-COPD patients with lower respiratory tract infection of AB, COPD patients with AB have higher resistance rate to common clinical antibiotics.

Key words: Chronic obstructive pulmonary disease, Acinetobacter baumannii, Drug resistance, Risk factors, Multivariate logistic regression analysis

CLC Number: 

  • R574
[1] Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetbacter baumannii [J]. Nat Rev Microbiol, 2007, 5(12): 939-951.
[2] 刘又宁, 曹彬, 王辉, 等. 中国九城市成人医院获得性肺炎微生物与临床特点调查[J]. 中华结核和呼吸杂志, 2012, 35(4): 739.
[3] Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections [J]. Lancet Infect Dis, 2008, 8(12): 751-762.
[4] Zheng YL, Wan YF, Zhou LY, et a1. Risk factors and mortality of patients with nosocomial earbapenem-resistant Acinetobacter baumannii pneumonia [J]. Am J Infect Control, 2013, 41(7): 59-63.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华内科杂志, 2013, 46(3): 254-261.
[6] Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[EB/OL].(2006-11-19)[2009-12] http://www.Goldcopd.com.
[7] MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease [J]. Proc Am Thorac Soc, 2008, 5(4): 530-535.
[8] 王冬梅. 慢性阻塞性肺疾病急性加重期痰培养及药敏结果分析[J]. 大家健康, 2015, 9(7): 49-50.
[9] Ye F, He LX, Cai BQ, et al. Spectrum and antimicrobial resistance of common pathogenic bacteria isolated from patients with acute exacerbation of chronic obstructive pulmonary disease in mainland of China [J]. Chin Med J(Engl), 2013, 126(12): 2207 -2214.
[10] Diaz E, Planas K, Rello J. Infection associated with the use of assisted-ventilation devices [J]. Enferm Infecc Microbiol Clin, 2008, 26(7): 465-470.
[11] 中华人民共和国卫生部.医院感染诊断标准(试行)[J]. 现代实用医学, 2003, 15(7): 460-465.
[12] 汪复, 张婴元.实用抗感染治疗学[M].北京: 人民卫生出版社, 2004: 7-8.
[13] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen [J]. Clin Microbiol Rev, 2008, 21(3): 538-582.
[14] 陈佰义, 何礼贤, 胡必杰, 等. 中国AB感染诊治与防控专家共识[J]. 中华医学杂志, 2012, 92(2): 76-82.
[15] Xiao-Min X, You-Fen F, Wei-Yun F, et al. Antibiotic resistance determinants of a group of multidrug-resistant Acinetobacter baumannii in China[J]. J Antibiot(Tokyo), 2014, 67(6):439-444.
[16] 王辉, 俞云松, 王明贵, 等. 替加环素体外药敏试验操作规程专家共识[J]. 中华检验医学杂志, 2013, 36(7): 584-587.
[17] Levin AS. Multi-resistant Acinetobacter infections: A role for sulbactam combinations in overcoming an emerging worldwide problem [J]. Clin Microbiol Infect, 2002, 8(3): 144-153.
[18] 李春辉. 医疗机构耐药菌MDR、XDR、PD的国际标准化定义专家建议(草案)[J]. 中国感染控制杂志, 2011, 12(3): 238-240.
[19] 张辉, 张小江, 徐英春, 等. 2012年中国CHINET不动杆菌属细菌耐药性监测[J]. 中国感染与化疗杂志, 2014, 14(5): 392-397.
[20] 胡付品, 朱德妹, 汪复, 等. 2014年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2015, 15(5): 401-410.
[21] 俞云松. 多药耐药AB-21世纪革兰阴性菌的“MRSA”[J]. 中华临床感染病杂志, 2009, 2(7): 65-68.
[22] Bacakoglu F, Korkmaz Ekren P, Ta?瘙塂bakan MS, et al. Multidrug-resistant acinetobacter baumannii infection in respiratory intensive care unit [J]. Mikrobiyol Bul, 2009, 43(4): 575-585.
[23] Wroblewska MM, Sawicka-Grzelak A, Marchel H, et al. Biofilm production by clinical strains of Acin, etobacter baumannii isolated from patients hospitalized in two tertiary care hospitals [J]. FEMS Immunol Med Microbiol, 2008, 53(1): 140-144.
[24] Munoz-Price LS, Carling P, Cleary T, et al. Control of a two-decade endemic situation with carbapenem-resistant Acinetobacter baumannii: electronic dissemination of a bundle of interventions [J]. Am J Infect Control, 2014, 42(5): 466-471.
[25] Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease [J]. Future Microbiol, 2012, 7(10): 1129-1132.
[26] Morgan DJ, Liang SY, Smith CL, et a1. Frequent multidrug-resistant Acinetobacter baumannii contamination of gloves, gowns, and hands of healthcare workers [J]. Infect Ctrl Hosp Epidemiol, 2010, 31(7): 716-721.
[27] Efrati S, Deutsch I, Antonelli M, et al. Vantilator-associated pneumonia: current status and future recommendations [J]. J Clin Monit Comput, 2010, 24(2): 161-168.
[28] Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study [J]. Antimicrob Agents Chemother, 2004, 48(1): 224-228.
[29] Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy[J].Chest, 2007, 131(1): 9-19.
[30] Rumbo C, Gato E, Lopez M, et al. Contribution of efflux pumps,porins,and β-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2013, 57(11): 5247-5257.
[31] 习慧明, 徐英春, 朱德妹, 等. 2010年中国CHINETAB耐药性监测[J]. 中国感染与化疗杂志, 2012, 12(2): 98-104.
[32] 张辉, 张小江, 徐英春, 等. 2011年中国CHINET不动杆菌属细菌耐药性监测[J]. 中国感染与化疗杂志, 2013, 13(5): 342-348.
[33] Rodriguez-Hernandez MJ, Pachon J, Pichardo C,et al. Imipenem,doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia [J]. J Antimicrob Chemother, 2000, 45(4): 493-501.
[1] GE Li-Juan, JIN Rui-Feng, WANG Ji-Wen, HU Xin-Sheng, LIKun. Association between the C1236T polymorphism in multi-drug resistance gene 1 and response to antiepileptic drug treatment in epileptic patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 99-102.
[2] LIU Huijun, WU Zhaoting, WANG Yuli, XU Mingyang, LIU Xiao, KANG Yan, WANG Hongmei. Risk factors and early intervention for postpartum hemorrhage caused by lower uterine segment atony [J]. Journal of Shandong University (Health Sciences), 2026, 64(5): 61-66.
[3] LIN Mingxia, LIU Guibin, MA Yanhua, LIAN Zhaoyu, REN Yangyang. ATPase copper transporting alpha mediated cuproptosis pathway and its value in cancer therapy [J]. Journal of Shandong University (Health Sciences), 2026, 64(4): 117-124.
[4] LU Chenlin, XU Lu, YANG Junfa, PAN Huaqin, NI Qingtao. Construction and validation of a risk prediction model for pulmonary encephalopathy associated with acute exacerbation of chronic obstructive pulmonary disease based on dynamic nomogram and machine learning [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 108-115.
[5] PANG Jinhong, SU Ping, QIAO Junpeng, CHEN Qiaoqiao, CHEN Xueyu, ZHAO Yingying, SHI Jie, SUN Xiaoru, LI Qiuchun, HE Ruiyan, FAN Yiou, CHI Weiwei. Association between modifiable cardiovascular risk factors clustering patterns and stroke in the elderly population [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 11-19.
[6] ZHANG Zheng, WANG Jianwei, YANG Yujuan, ZHANG Yu, SONG Xicheng. Immunoglobulin E changes and risk factors in asthma children between 2008 and 2019 [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 32-36.
[7] LI Jing, HAO Panpan. Association between the heart rate variation and the prognosis in patients with acute heart failure at hospital admission and discharge [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 75-82.
[8] CHENG Zhenyu, LAI Qingguo, WU Mengtao. Advances in influencing factors of in-stent restenosis after iliofemoral vein stenting [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 112-117.
[9] CHENG Yueqi, WANG Fei, YU Lixiang, ZHENG Chao, YU Zhigang. Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 17-24.
[10] WANG Zheyu, XU Yi, ZHAO Changbo, YANG Shuofei, NI Qihong, CHEN Jiaquan, WANG Weilun, LI Yinan, GUO Xiangjiang, YE Meng, ZHANG Lan, XUE Guanhua. Risk factors and management for iliac branch occlusion after endovascular abdominal aortic aneurysm repair [J]. Journal of Shandong University (Health Sciences), 2024, 62(9): 101-107.
[11] SHEN Yongchun, WEN Fuqiang. Research progress of mitochondrial damage-associated molecular patterns as biomarkers for chronic obstructive pulmonary disease [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 16-20.
[12] LIU Chao, DIAO Tingting, ZHANG Hongji, LIU Hongwei, YANG Yongrui, LI Xiaofei. Application value of matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the detection of drug resistance of Mycobacterium tuberculosis [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 61-67.
[13] LI Jian, SUN Yun. Risk factors for death within 2 years in new maintenance haemodialysis patients [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 48-53.
[14] HAO Yan, CUI Limei, CHEN Ying, YANG Yujuan, SONG Xicheng. Advances of metabolomics in airway inflammatory diseases [J]. Journal of Shandong University (Health Sciences), 2024, 62(12): 117-124.
[15] LIU Na, WANG Nana, JI Bing, DING Xuemei, LIU Yaxin, FANG Xiaoqing, ZHANG Xiaoli. Distribution and drug resistance changes of pathogenic bacteria in hospitalized elderly inpatients from 2012 to 2021 [J]. Journal of Shandong University (Health Sciences), 2023, 61(6): 29-40.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!